Overview of Medicare Part D prescription drug benefit: Potential implications for patients with psychotic disorders

被引:1
|
作者
Rosenberg, Jack A.
机构
[1] Long Isl Univ, Int Drug Informat Ctr, Brooklyn, NY 11201 USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA
关键词
costs; economics; healthbenefit programs; laws; pharmacists; prescriptions; psychotherapeutic agents; psychotic disorders;
D O I
10.2146/ajhp060592
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Medicare Part D prescription drug benefits are reviewed. Potential implications, for patients with psychotic disorders in relation to Medicare Part D are discussed. Summary. The newly created Medicare Part D provides prescription drug benefits to many individuals formerly without prescription benefits and, possibly, lower-cost benefits to those who previously relied on other benefits., Participating prescription plans use a variety of pharmacy management tools to minimize costs while providing benefit plans that meet Part D requirements for composition and coverage. Patients then have the challenge of choosing a prescription drug plan that will best satisfy their prescriptions needs. Conclusion. The rollout of Part D has not been without problems, and although more Medicare participants are receiving prescription drug benefits at a greater savings,there are concerns that Part D may not provide adequate coverage for all patients or for patients requiring certain types of medications, especially some psychotropic medications. Pharmacists have voiced concerns about the Medicare Part D drug plan in regard to both the degree of coverage it provides to enrollees and the difficulty in administering the benefit.
引用
收藏
页码:S18 / S23
页数:6
相关论文
共 50 条
  • [1] Medicare Part D Prescription Drug Benefit - Part 1 of 2
    Klein, Cathy A.
    NURSE PRACTITIONER, 2006, 31 (02): : 61 - 61
  • [2] Trends in the prescription drug plans delivering the Medicare Part D Prescription Drug Benefit
    Brill, Joel V.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (15) : S3 - S6
  • [3] The effect of the medicare Part D prescription benefit on drug utilization and expenditures
    Yin, Wesley
    Basu, Anirban
    Zhang, James X.
    Rabbani, Atonu
    Meltzer, David O.
    Alexander, G. Caleb
    ANNALS OF INTERNAL MEDICINE, 2008, 148 (03) : 169 - 177
  • [4] The Impact of the Medicare Part D Prescription Benefit on Generic Drug Use
    James X. Zhang
    Wesley Yin
    Shawn X. Sun
    G. Caleb Alexander
    Journal of General Internal Medicine, 2008, 23 : 1673 - 1678
  • [5] The impact of the Medicare Part D prescription benefit on generic drug use
    Zhang, James X.
    Yin, Wesley
    Sun, Shawn X.
    Alexander, G. Caleb
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (10) : 1673 - 1678
  • [6] Implementing the medicare part D prescription drug benefit program: Implications for public health policy and practice
    Rosenbaum, S
    Teitelbaum, J
    PUBLIC HEALTH REPORTS, 2005, 120 (04) : 467 - 469
  • [7] Differential take-up of the medicare part D prescription drug benefit
    Rabbani, A.
    Yin, W.
    Zhang, J. X.
    Sun, S. X.
    Alexander, G. C.
    VALUE IN HEALTH, 2008, 11 (03) : A12 - A13
  • [8] Differential take-up of the medicare part D prescription drug benefit
    Rabbani, A.
    Yin, W.
    Zhang, J. X.
    Sun, S.
    Alexander, G. C.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 : 282 - 282
  • [9] The new medicare part D prescription drug benefit: An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation
    Evans-Molina, Carmella
    Regan, Susan
    Henault, Lori E.
    Hylek, Elaine M.
    Schwartz, Gregory R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (07) : 1038 - 1043
  • [10] The impact of the medicare part D prescription drug benefit on prescription utilization and out-of-pocket expenditures
    Yin, W.
    Basu, A.
    Zhang, J.
    Rabbani, A.
    Meltzer, D.
    Alexander, G.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (03) : 620 - 620